Zevra Therapeutics (NASDAQ:ZVRA) Upgraded by Wall Street Zen to “Buy” Rating

Posted by Stanley Muller on Jul 12th, 2026

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Sunday.

Other research analysts also recently issued research reports about the stock. BTIG Research reissued a “buy” rating and issued a $27.00 target price (up from $23.00) on shares of Zevra Therapeutics in a research note on Tuesday, June 9th. Canaccord Genuity Group raised their price target on shares of Zevra Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Tuesday, June 9th. HC Wainwright reissued a “buy” rating and issued a $26.00 price objective on shares of Zevra Therapeutics in a research report on Tuesday, June 23rd. Guggenheim upped their price objective on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. Finally, Weiss Ratings lowered shares of Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Friday, May 22nd. Nine research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.29.

Get Our Latest Analysis on ZVRA

Zevra Therapeutics Price Performance

Zevra Therapeutics stock traded down $0.59 during mid-day trading on Friday, hitting $13.35. 2,060,244 shares of the company were exchanged, compared to its average volume of 1,433,624. The business’s 50 day simple moving average is $12.10 and its two-hundred day simple moving average is $10.21. The company has a market capitalization of $789.25 million, a P/E ratio of 6.71 and a beta of 0.85. Zevra Therapeutics has a 12-month low of $7.16 and a 12-month high of $15.03.

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.12. The business had revenue of $36.22 million for the quarter, compared to the consensus estimate of $31.96 million. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%. Equities research analysts predict that Zevra Therapeutics will post 0.56 earnings per share for the current year.

Institutional Investors Weigh In On Zevra Therapeutics

Institutional investors have recently bought and sold shares of the stock. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new stake in shares of Zevra Therapeutics during the 4th quarter worth $53,000. Russell Investments Group Ltd. boosted its holdings in Zevra Therapeutics by 235.7% in the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after acquiring an additional 4,475 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Zevra Therapeutics by 617.5% in the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after acquiring an additional 8,552 shares during the last quarter. Creative Planning purchased a new stake in Zevra Therapeutics during the second quarter valued at about $92,000. Finally, Qube Research & Technologies Ltd purchased a new stake in Zevra Therapeutics during the second quarter valued at about $99,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

About Zevra Therapeutics

(Get Free Report)

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.